BioSeeker Group publishes new repot on Ion Channel Assays in the Drug Discovery Process

BioSeeker Group AB have recognized the interest and need for a comprehensive study within the field of ion channel assay technology. We have identified 23 companies with a strong focus within this field. "Ion Channel Assays in the Drug Discovery Process" compiles and assesses the available and future possibilities in ion channel assays. It provides an outlook at the competitive landscape of companies in this field, and guides the user to technologies that suite different segments of the drug discovery process.

BioSeeker Group AB have recognized the interest and need for a comprehensive study within the field of ion channel assay technology. We have identified 23 companies with a strong focus within this field. "Ion Channel Assays in the Drug Discovery Process" compiles and assesses the available and future possibilities in ion channel assays. It provides an outlook at the competitive landscape of companies in this field, and guides the user to technologies that suite different segments of the drug discovery process.

Ion channels play an important role in numerous cell types and occur as large families of related genes with cell-specific expression patterns. Considering the publication of the human genome and the progress in transcription profiling revealing the tissue specific distributions of ion
channels, they will play a much more important role as therapeutic drug targets in the future. Combined with cell-based assays providing biologically relevant information to genomic and proteomic information, ion channels will be a favorable class of selective, tissue specific, drug
targets. With the demand for screening large compound collections against an increasing number of therapeutic targets, there has been a stimulated requirement of developing automation, miniaturization and high throughput assay systems. The shrinking assay volume requires the development of homogenous assay formats and higher detection sensitivity. The technology
employed for ion channel screening includes, binding assays, fluorometric imaging and voltage sensing.

Companies included in the report:
Abbott laboratories, ALA Instruments, Aurora Biomed Inc, Aurora Biosciences, AVIVA Biosciences, Axon Instruments, BioFocus/Cambridge Drug Discovery, Calipher Technologies, Cambridge Drug Discovery Holdings Ltd., CeNeS, Cellectricon AB, Cytion, Cytocentrics (CCS) GmbH, Cytoplex, Essen Instruments, EVOTEC/Genion, IonGate Biosciences, Molecular Devices Corp, Nanion Technologies, Packard Bioscience, Scion Pharmaceuticals Inc., Sophion Bioscience A/S.

For more information please contact us at BioInfo@BioSeeker.com